Novavax Inc - Asset Resilience Ratio
Novavax Inc (NVAX) has an Asset Resilience Ratio of 42.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Novavax Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Novavax Inc's Asset Resilience Ratio has changed over time. See NVAX book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Novavax Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novavax Inc (NVAX) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $494.45 Million | 42.03% |
| Total Liquid Assets | $494.45 Million | 42.03% |
Asset Resilience Insights
- Very High Liquidity: Novavax Inc maintains exceptional liquid asset reserves at 42.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novavax Inc Industry Peers by Asset Resilience Ratio
Compare Novavax Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Novavax Inc (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Novavax Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.03% | $494.45 Million | $1.18 Billion | +16.85pp |
| 2024-12-31 | 25.18% | $392.89 Million | $1.56 Billion | +24.60pp |
| 2023-12-31 | 0.58% | $10.42 Million | $1.80 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $2.58 Billion | -- |
| 2020-12-31 | 9.96% | $157.65 Million | $1.58 Billion | -- |
| 2019-12-31 | 0.00% | $0.00 | $172.96 Million | -- |
| 2018-12-31 | 10.57% | $21.98 Million | $207.98 Million | -6.29pp |
| 2017-12-31 | 16.86% | $51.00 Million | $302.49 Million | -6.25pp |
| 2016-12-31 | 23.11% | $91.13 Million | $394.30 Million | -12.52pp |
| 2015-12-31 | 35.63% | $137.55 Million | $386.04 Million | -13.54pp |
| 2014-12-31 | 49.17% | $135.72 Million | $276.00 Million | +43.41pp |
| 2013-12-31 | 5.76% | $13.60 Million | $235.94 Million | -20.34pp |
| 2012-12-31 | 26.10% | $26.71 Million | $102.34 Million | +19.78pp |
| 2011-12-31 | 6.32% | $4.21 Million | $66.58 Million | -25.24pp |
| 2010-12-31 | 31.55% | $23.61 Million | $74.84 Million | +26.65pp |
| 2009-12-31 | 4.90% | $4.19 Million | $85.61 Million | -4.19pp |
| 2008-12-31 | 9.09% | $6.96 Million | $76.62 Million | -37.07pp |
| 2007-12-31 | 46.16% | $42.14 Million | $91.29 Million | -8.35pp |
| 2006-12-31 | 54.51% | $66.43 Million | $121.88 Million | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more